Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 6OTHER 5NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1

Conditions

Prostatic Neoplasms 2Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 388Specimen Handling 377Magnetic Resonance Spectroscopy 328Radiotherapy 306Biopsy 273Cisplatin 258Carboplatin 255Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 183Bevacizumab 181Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 141Taxes 127Docetaxel 122Chemotherapy, Adjuvant 114Oxaliplatin 113fludarabine phosphate 111Methotrexate 108Rituximab 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × IT-101 × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT03531827 2022-07-12

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡